Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin alphaVbeta3

Paulus J, Sewald N (2022)
Frontiers in Chemistry 10: 869639.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Abstract / Bemerkung
An integrin alphaVbeta3-targeting linear RGD mimetic containing a small-molecule drug conjugate (SMDC) was synthesized by combining the antimitotic agent monomethyl auristatin E (MMAE), an enzymatically cleavable Val-Ala-PABC linker with a linear conjugable RGD mimetic. The structure proposal for the conjugable RGD mimetic was suggested upon the DAD mapping analysis of a previously synthesized small-molecule RGD mimetic array based on a tyrosine scaffold. Therefore, a diversifying strategy was developed as well as a novel method for the partial hydrogenation of pyrimidines in the presence of the hydrogenolytically cleavable Cbz group. The small-molecule RGD mimetics were evaluated in an ELISA-like assay, and the structural relationships were analyzed by DAD mapping revealing activity differences induced by structural changes as visualized in dependence on special structural motifs. This provided a lead structure for generation of an SMDC containing the antimitotic drug MMAE. The resulting SMDC containing a linear RGD mimetic was tested in a cell adhesion and an in vitro cell viability assay in comparison to reference SMDCs containing cRGDfK or cRADfK as the homing device. The linear RGD SMDC and the cRGDfK SMDC inhibited adhesion of alphaVbeta3-positive WM115 cells to vitronectin with IC50 values in the low M range, while no effect was observed for the alphaVbeta3-negative M21-L cell line. The cRADfK SMDC used as a negative control was about 30-fold less active in the cell adhesion assay than the cRGDfK SMDC. Conversely, both the linear RGD SMDC and the cRGDfK SMDC are about 55-fold less cytotoxic than MMAE against the alphaVbeta3-positive WM115 cell line with IC50 values in the nM range, while the cRADfK SMDC is 150-fold less cytotoxic than MMAE. Hence, integrin binding also influences the antiproliferative activity giving a targeting index of 2.8. Copyright © 2022 Paulus and Sewald.
Erscheinungsjahr
2022
Zeitschriftentitel
Frontiers in Chemistry
Band
10
Art.-Nr.
869639
eISSN
2296-2646
Page URI
https://pub.uni-bielefeld.de/record/2962817

Zitieren

Paulus J, Sewald N. Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin alphaVbeta3. Frontiers in Chemistry . 2022;10: 869639.
Paulus, J., & Sewald, N. (2022). Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin alphaVbeta3. Frontiers in Chemistry , 10, 869639. https://doi.org/10.3389/fchem.2022.869639
Paulus, J., and Sewald, N. (2022). Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin alphaVbeta3. Frontiers in Chemistry 10:869639.
Paulus, J., & Sewald, N., 2022. Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin alphaVbeta3. Frontiers in Chemistry , 10: 869639.
J. Paulus and N. Sewald, “Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin alphaVbeta3”, Frontiers in Chemistry , vol. 10, 2022, : 869639.
Paulus, J., Sewald, N.: Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin alphaVbeta3. Frontiers in Chemistry . 10, : 869639 (2022).
Paulus, Jannik, and Sewald, Norbert. “Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin alphaVbeta3”. Frontiers in Chemistry 10 (2022): 869639.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 35480387
PubMed | Europe PMC

Suchen in

Google Scholar